Low Dose Interleukin-2 Selectively Expands Circulating Regulatory T Cells but Fails to Promote Liver Allograft Tolerance in Humans

The authors conducted a clinical trial in stable liver recipients two to six years post-transplant to determine the capacity of low dose interleukin-2 to suppress allospecific immune responses and allow for the complete discontinuation of maintenance immunosuppression.